Semaglutide cardiovascular outcomes in diabetes
New England Journal of Medicine
2018
Study summary
Semaglutide evaluated for glycemic control and cardiovascular risk.
Peptides studied
Goals studied
Stack studied
Metabolic Stack
Key findings
Improved glucose regulation and reduced cardiovascular risk markers.
Study details
Study type
randomized clinical trial
Journal
New England Journal of Medicine
DOI / PubMed
10.1056/NEJMoa1800869
Year
2018
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.
